All In MedTech

FDA Clearance Tracker · P250003-S008

Embrace(TM) Hydrogel Embolic System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 23, 2026

Approved

Time to decision

178 days

Received Apr 28, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P250003-S008
Device name
Embrace(TM) Hydrogel Embolic System
Applicant location
Bedford, MA
Received
Apr 28, 2026
Decided
Oct 23, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P250003

Device type

Device class
Class III

Every decision under product code QVG

FDA's approval statement

As written in FDA's record.

This device is indicated for embolization of hypervascular tumors in peripheral arteries = 5mm and peripheral arterial bleeds in vessels = 6mm.

Source documents

Other decisions for Instylla, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.